The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Treatment patterns and systemic therapy outcomes for patients with salivary duct carcinoma and adenocarcinoma NOS.
 
Luana Guimarães Sousa
No Relationships to Disclose
 
Kaiwen Wang
No Relationships to Disclose
 
Danice Torman
No Relationships to Disclose
 
Bailee Binks
No Relationships to Disclose
 
Clark Andersen
No Relationships to Disclose
 
Whitney E Lewis
Honoraria - Hematology/Oncology Pharmacy Association; Power-Pak CE
Consulting or Advisory Role - AstraZeneca
 
Melvin Rivera
No Relationships to Disclose
 
Diana Kaya
No Relationships to Disclose
 
Adel K. El-Naggar
No Relationships to Disclose
 
Ehab Y. Hanna
No Relationships to Disclose
 
Bita Esmaeli
No Relationships to Disclose
 
Steven J. Frank
No Relationships to Disclose
 
Diana Bell
No Relationships to Disclose
 
Bonnie S. Glisson
Research Funding - CUE Biopharma (Inst); ISA Pharmaceuticals (Inst); Medimmune (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Abbvie/Stemcentrx; ISA Pharmaceuticals
 
Jordi Rodon Ahnert
Consulting or Advisory Role - Ellipses Pharma; Ionctura; Kelun; Lilly; Merck Sharp & Dohme; Molecular Partners; Novartis; NovellusDx; Orion; Peptomyc; Pfizer; Roche/Genentech; SERVIER; Spectrum Pharmaceuticals
Research Funding - Bayer; BioAtla; Blueprint Medicines; CytomX Therapeutics; Genmab; GlaxoSmithKline; Ipsen; Kelun; Novartis; Pfizer; Spectrum Pharmaceuticals; Symphogen; Takeda/Millennium; Tocagen
Travel, Accommodations, Expenses - Cancer Core Europe; Department of Defense; ESMO; Huntsman Cancer Institute; Karolinska Cancer Institute; King Abdullah International Medical Research Center; Louisiana State University; Molecular Partners
Other Relationship - Chinese University of Hong Kong; Elsevier; European Journal of Cancer; GlaxoSmithKline; SOLTI; Vall d'Hebron University Hospital Institute of Oncology
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Honoraria - Mayo Clinic; Rutgers Cancer Institute of New Jersey
Consulting or Advisory Role - Aduro Biotech; Alkermes; Debiopharm Group; eFFECTOR Therapeutics; Genentech; IBM; Immunomedics; Inflection Biosciences; Jackson Laboratory for Genomic Medicine; Kolon Life Sciences; Mersana; Origimed; PACT Pharma; Parexel International; Pfizer; Puma Biotechnology; Roche; Samsung Bioepis; Seagen; Silverback Therapeutics; Spectrum Pharmaceuticals; Tyra Biosciences; Xencor; Zentalis; Zymeworks
Speakers' Bureau - Chugai Pharma
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (I); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Jounce Therapeutics (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Beth Israel Deaconess Medical Center; Taiho Pharmaceutical
 
J. Jack Lee
Honoraria - AstraZeneca
 
Renata Ferrarotto
Consulting or Advisory Role - Bicara Therapeutics; Carevive Systems; Intellisphere; Prelude Therapeutics; Regeneron
Research Funding - AstraZeneca/MedImmune (Inst); Ayala Pharmaceuticals (Inst); Ayala Pharmaceuticals (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Merck Serono (Inst); Pfizer/EMD Serono (Inst); Prelude Therapeutics (Inst); Prelude Therapeutics (Inst)